Iscalimab (CFZ-533), an IgG1 anti CD40 antibody reported positive data in a phase 2 study of iscalimab versus a standard of care (SOC) arm containing the calcineurin inhibitor tacrolimus (TAC) in de novo kidney transplant recipients. This evidence concerns the gene CD40 and kidney transplant.